Bayer teams up with Twist: The German drugmaker entered into a drug discovery deal with California biotech Twist Bioscience. Twist will use its synthetic antibody libraries to discover antibodies against targets selected by Bayer, which will have the option to license them. Twist is eligible for up to $188 million in upfront and milestones payments as well as tiered royalties on potential product sales. — Ayisha Sharma
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.